Treatment Options Continue to Increase in Low-Risk MDS
November 3rd 2021Azanucleosides, such as azacitidine, remain the backbone of disease-modifying therapy for patients with myelodysplastic syndromes, however, new adjuncts are leading to longer remissions and disease-free survival in patients with low-risk disease.
Read More
Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial
October 14th 2021The initiation of the phase 3 ENHANCE trial looks to build on the generally early response to azacitidine with the addition of magrolimab, a first-in-class monoclonal antibody, for patients with intermediate-, high-, and very high–risk myelodysplastic syndrome.
Read More
Pivotal MagnetisMM-3 Trial Aims to Add Elranatamab in Multiple Myeloma Treatment
September 27th 2021Patients with relapsed/refractory multiple myeloma, particularly those who have failed a prior BCMA–targeted therapy, represent a population with an unmet need for effective treatment options. Investigators are hoping to help fill this void with the initiation of the phase 2 MagnetisMM-3 study.
Read More
LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
September 14th 2021Large surface area microparticle docetaxel administered via direct intramural injection and intravesical instillations was found to be safe and showed preliminary signs of efficacy in patients with high-risk non-muscle invasive bladder cancer.
Read More
Lutetium-PSMA Appears Safe in Locally Advanced High-Risk Prostate Cancer
September 11th 2021Treatment with neoadjuvant lutetium prostate-specific membrane antigen followed by radical prostatectomy exhibited a favorable safety profile in patients with locally advanced high-risk prostate cancer.
Read More
Kaiku Health and Novartis Collaborate on Specialized Digital Patient Monitoring Technology
June 15th 2021Kaiku Health has announced that they are partnering with the global healthcare company Novartis to develop a digital patient monitoring and management system specifically for patients with melanoma who are receiving BRAF/MEK combination therapies.
Read More